Respiratory Trend Report

Week ending January 10th, 2026

HealthTrackRx
Trend Update

Respiratory season remains in full swing, with several respiratory pathogens continuing to demonstrate elevated positivity rates nationwide. Providers are encouraged to reinforce hygiene best practices and contact precautions when caring for symptomatic individuals.

Respiratory Trend Report

Week ending January 10th, 2026

Get Updates

HealthTrackRx
Trend Update

Infection Trends

Influenza A/B positivity rates remain above 10% nationally, with a combined positivity rate of 16.1% from December 28 to January 3, decreasing to 12.2% for the week ending January 10.
Respiratory Syncytial Virus (RSV) also remains elevated, with positivity rates above 5% nationally (6.1% from December 28–January 3 and 5.6% from January 4–January 10).
Human Parainfluenza viruses (types 1–4) continue to demonstrate positivity rates above 2%, although this represents a downward trend from the 7–8% rates observed in the fall of 2025.
COVID-19 prevalence has remained low and stable, with positivity rates near 2% (2.1% for the week ending January 3 and 2.0% for the week ending January 10).
Seasonal Coronaviruses (229E, NL63, HKU1, and OC43) have shown an upward trend since fall 2025, increasing from 5.8% during December 28–January 3 to 6.1% during January 4–January 10.

Note that the modest declines observed across several respiratory pathogens may be influenced by reduced testing volumes during the holiday period and may not reflect a true decrease in transmission.

Infection Trends

Influenza A/B positivity rates remain above 10% nationally, with a combined positivity rate of 16.1% from December 28 to January 3, decreasing to 12.2% for the week ending January 10.
Respiratory Syncytial Virus (RSV) also remains elevated, with positivity rates above 5% nationally (6.1% from December 28–January 3 and 5.6% from January 4–January 10).
Human Parainfluenza viruses (types 1–4) continue to demonstrate positivity rates above 2%, although this represents a downward trend from the 7–8% rates observed in the fall of 2025.
COVID-19 prevalence has remained low and stable, with positivity rates near 2% (2.1% for the week ending January 3 and 2.0% for the week ending January 10).
Seasonal Coronaviruses (229E, NL63, HKU1, and OC43) have shown an upward trend since fall 2025, increasing from 5.8% during December 28–January 3 to 6.1% during January 4–January 10.

Note that the modest declines observed across several respiratory pathogens may be influenced by reduced testing volumes during the holiday period and may not reflect a true decrease in transmission.

Seasonal Outlook

RSV and Influenza are expected to remain elevated throughout the winter season.
Rhinovirus/Enterovirus continues to trend downward but remains the pathogen with the highest overall positivity rate.
COVID-19 activity remains low and stable, with no significant changes observed.
Seasonal Coronaviruses (229E, NL63, HKU1, OC43) have increased to positivity rates exceeding 6%, compared to 1–3% in fall 2025, warranting continued monitoring through the winter months.

Seasonal Outlook

RSV and Influenza are expected to remain elevated throughout the winter season.
Rhinovirus/Enterovirus continues to trend downward but remains the pathogen with the highest overall positivity rate.
COVID-19 activity remains low and stable, with no significant changes observed.
Seasonal Coronaviruses (229E, NL63, HKU1, OC43) have increased to positivity rates exceeding 6%, compared to 1–3% in fall 2025, warranting continued monitoring through the winter months.

Trending Up

Coronaviruses (229E, NL63, HKU1, OC43)
Human Metapneumovirus

Trending Down

Rhinovirus/Enterovirus
Parainfluenza Viruses (types 1-4)

Remaining Level

Adenovirus
COVID-19 Coronavirus (SARS-CoV-2)
Influenza A/B
Respiratory Syncytial Virus
Enterovirus D68

Trending Up

Coronaviruses (229E, NL63, HKU1, OC43)
Human Metapneumovirus

Trending Down

Rhinovirus/Enterovirus
Parainfluenza Viruses (types 1-4)

Remaining Level

Adenovirus
COVID-19 Coronavirus (SARS-CoV-2)
Influenza A/B
Respiratory Syncytial Virus
Enterovirus D68

7 Day Influenza Virus A/B Map

This report reflects observed trends in HealthTrackRx testing positivity data, does not convey medical advice, and is provided for informational purposes only. Individuals experiencing respiratory symptoms should consult with their healthcare provider.

Download Respiratory Trend Reports [PDF]

View Reports+